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Abstract
Background: Clostridium difficile infection (CDI) is the leading infectious cause of nosocomial diarrhea. Hospitalized
patients are at increased risk of developing CDI because they are exposed to C. difficile spores through contact with
the hospital environment and often receive antibiotics and other medications that can disrupt the integrity of the
indigenous intestinal microbiota and impair colonization resistance. Using whole metagenome shotgun sequencing,
we examined the diversity and composition of the fecal microbiota in a prospective cohort study of 98 hospitalized
patients.
Results: Four patients had asymptomatic C. difficile colonization, and four patients developed CDI. We observed
dramatic shifts in the structure of the gut microbiota during hospitalization. In contrast to CDI cases, asymptomatic
patients exhibited elevated relative abundance of potentially protective bacterial taxa in their gut at the onset of C.
difficile colonization. Use of laxatives was associated with significant reductions in the relative abundance of
Clostridium and Eubacterium; species within these genera have previously been shown to enhance resistance
to CDI via the production of secondary bile acids. Cephalosporin and fluoroquinolone exposure decreased the
frequency of Clostridiales Family XI Incertae Sedis, a bacterial family that has been previously associated with
decreased CDI risk.
Conclusions: This study underscores the detrimental impact of antibiotics as well as other medications, particularly
laxatives, on the intestinal microbiota and suggests that co-colonization with key bacterial taxa may prevent C. difficile
overgrowth or the transition from asymptomatic C. difficile colonization to CDI.
Keywords: Clostridium difficile infection, Whole metagenome shotgun sequencing, Intestinal microbiota, Antimicrobials,
Medications
Background
Clostridium difficile infection (CDI) is the leading cause
of infectious diarrhea in hospitalized patients. In the
USA alone, there are an estimated 453,000 cases and
29,300 deaths from CDI each year [1]. CDI is associated
with a wide range of syndromes, from asymptomatic
colonization to mild diarrhea or more severe pseudomem-
branous colitis that may progress to toxic megacolon,
intestinal perforation, sepsis, and death [2]. Despite ad-
vances in infection control practices and the development
of new treatment options, there has been a steady increase
in the incidence and severity of CDI in the last decade and
outbreaks continue to occur in hospitals and health-care
institutions worldwide [3, 4].
Hospitalized patients are at increased risk of developing
CDI because they are exposed to C. difficile spores
through contact with the hospital environment and often
receive broad-spectrum antimicrobials that disrupt the in-
tegrity of the indigenous intestinal microbiota and impair
colonization resistance (i.e., the ability of the microbiota
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to prevent the establishment of enteropathogens like C.
difficile in the gut). Nearly all classes of antibiotics have
been associated with CDI, but clindamycin, penicillins,
cephalosporins, and fluoroquinolones seem to pose the
greatest risk [5–7]. Additional risk factors for CDI include
advanced age, underlying diseases, gastrointestinal sur-
gery, nasogastric tube feeding, and use of proton pump in-
hibitors (PPIs, a class of medications that inhibit the
production of gastric acid in the stomach) [2, 8].
Among patients who acquire C. difficile in their gut,
some will remain asymptomatically colonized while
others may go on to develop diarrhea or more severe
forms of CDI. Differences in pathogen or host factors
like the immune status or the integrity of the intestinal
microbiota may affect the clinical presentation of CDI.
In hospitals and health-care facilities, asymptomatic car-
riers often outnumber symptomatic patients and may
represent a considerable reservoir of C. difficile that con-
tributes to environmental contamination and disease
transmission among patients [9, 10]. It has been sug-
gested that patients with asymptomatic C. difficile
colonization are at decreased risk of developing CDI, but
a recent meta-analysis has suggested this may not be the
case [11, 12]. Previously, we showed that patients who
have higher levels of Clostridiales Family XI Incertae
Sedis were at a decreased risk of developing CDI [13],
and others have demonstrated that the presence of sec-
ondary bile acid-producing bacteria such as Clostridium
scindens was associated with resistance to CDI [14].
Despite the strong relationship between the intestinal
microbiota and CDI susceptibility, the impact of non-
antimicrobial medications on the microbiota has not
been examined in detail.
In this study, we prospectively examined the intestinal
microbiota of hospitalized patients at-risk for CDI. Using
whole metagenome shotgun (WMGS) DNA sequencing,
we specifically assessed (i) the changes in the relative
abundance of microbial taxa in patients who were iden-
tified as colonized or infected with C. difficile and (ii)
the impact of antibiotics and other medications on the
diversity and composition of the intestinal microbiota
among patients who were neither colonized nor infected
with C. difficile. We postulated that protective micro-
biota members which are thought to mediate competi-
tive inhibition against C. difficile (such as Clostridiales
Family XI Incertae Sedis and non-toxigenic C. difficile)
[13, 15] or limit the germination and growth of C. diffi-
cile via the production of secondary bile acids (Clostrid-
ium and Eubacterium genera) [14, 16] are present in
colonized but not in infected patients. We also hypothe-
sized that not only antibiotics but also other medications
such as PPIs will decrease the overall diversity of the in-
testinal microbiota and increase the relative abundance
of opportunistic microorganisms such as enterococci
and yeasts [17–20]. We report that the relative abun-
dance of Clostridiales Family XI Incertae Sedis, Clostrid-
ium, and Eubacterium is higher in asymptomatically
colonized patients than in CDI cases. Moreover, antibi-
otics and other medications such as laxatives have sub-
stantial effects on the intestinal microbiota of hospitalized
patients and reduce the relative abundance of these poten-
tially protective bacterial taxa. Even though the term “in-
fected” is sometimes used to designate people who are
asymptomatically colonized with C. difficile, in this report,
we will use the term “infected” (or CDI) to describe pa-
tients who are symptomatic and “colonized” to describe




A total of 104 patients were enrolled in the study. Four
patients did not provide any stool sample, and six stool
samples were excluded because of poor library quality or
sequencing results; this left a total of 98 patients and
229 fecal samples in the study. We analyzed a median of
two fecal samples per patient (range, 1–15). Patient
characteristics are shown in Table 1. The majority of pa-
tients (63 %) suffered from osteoarthritis and were ad-
mitted for orthopedic surgery; most of them (89 %)
received cefazolin (a first-generation cephalosporin) as
perioperative antimicrobial prophylaxis. One patient
(1.0 %) had asymptomatic C. difficile colonization on ad-
mission, three patients (3.1 %) became asymptomatically
colonized during hospitalization, and four patients
(4.1 %) developed hospital-acquired CDI. All of the CDI
cases had diarrhea during their initial episode but none
of them developed recurrent CDI.
WMGS sequencing
Fecal samples were evaluated by WMGS sequencing to
assess the diversity and composition of the intestinal
microbiota. We obtained a median of 6.1 million high-
quality reads per sample (range, 0.6–41.9 million). The
proportion of human DNA reads was highly variable
(range, 0.1–94.9 %) but half of the samples contained
<20 % of human reads. After removing the host DNA,
we computed the frequency of 16S ribosomal RNA
(rRNA) genes in each sample as a measure of bacterial
DNA content. The mean frequency of 16S rRNA
genes per megabase (Mb) of sequence data was 0.39
(standard deviation 0.18). Across all samples, we ob-
tained a median of 2.1 % of reads (range, 0.1–4.8 %)
with a hit to MetaPhlAn2’s taxonomic marker data-
base, with at least 2700 hits per sample. Bacteroides
(99.0 %), Prevotella (98.0 %), and Subdoligranulum
(98.0 %) were the most common genera, and Por-
phyromonadaceae (100 %), Bacteroidaceae (99.0 %),
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Enterobacteriaceae (98.0 %), Prevotellaceae (98.0 %),
and Ruminococcaceae (98.0 %) were the most com-
mon families detected across patients (percentage of
patients in which the corresponding taxa was
detected).
C. difficile detection
Results from the detection of C. difficile or its toxins in
eight patients who developed C. difficile colonization
(n = 4) or infection (n = 4) are provided in Table 2.
Out of these eight patients, six had a positive C.
Table 1 Characteristics of the study patients
Variable Neither C. difficile infection





Age, mean years (range) 74 (61–91) 71 (66–80) 74 (71–78)
Male sex 44 (49) 2 (50) 2 (50)
Horn’s indexa, median (range) 1 (1–2) 1 (1–1) 1 (1–2)
Duration of hospitalizationb, median days (range) 5 (1–69) 21 (2–61) 5 (1–15)
Hospitalization in past 12 monthsc 11 (12) 0 0
Fecal specimens analyzed, median (range) 2 (1–12) 4 (1–15) 2 (1–4)
Reason for hospital admission
Osteoarthritis/Rheumatoid arthritis 62 (69) 0 1 (25)
Pneumonia 8 (9) 1 (25) 1 (25)
Cellulitis 4 (4) 1 (25) 1 (25)
Fever 2 (2) 0 0
Chronic obstructive pulmonary disease 3 (3) 0 0
Othersd 11 (12) 2 (50) 1 (25)
Medication useb
Non-steroidal anti-inflammatory drugs 33 (37) 4 (100) 2 (50)
Proton pump inhibitors 26 (29) 2 (50) 2 (50)
Glucocorticoids 12 (13) 2 (50) 1 (25)
Opioids 25 (28) 3 (75) 1 (25)
Laxatives 16 (18) 3 (75) 0
Propulsive agents 3 (3) 0 0
Antipropulsive agents 1 (1) 1 (25) 0
Chemotherapeutic agents 0 0 1 (25)
Any antibiotic 80 (89) 4 (100) 4 (100)
Cephalosporins 60 (67) 1 (25) 1 (25)
Fluoroquinolones 13 (14) 2 (50) 0
Penicillin with β-lactamase inhibitors 12 (13) 3 (75) 1 (25)
Vancomycin (intravenous) 7 (8) 2 (50) 0
Carbapenems 6 (7) 2 (50) 2 (50)
Penicillins 5 (6) 0 0
Azithromycin 4 (4) 1 (25) 0
Metronidazole 3 (3) 1 (25) 0
Cotrimoxazole 2 (2) 0 0
Otherse 2 (2) 3 (75) 0
Data are number (%) of subjects unless otherwise specified
aEvaluated at study enrollment
bFrom admission until diagnosis of C. difficile infection or colonization (for infected and colonized patients, respectively) or until discharge (for patients with
neither infection nor colonization)
cInformation about prior hospitalization was unknown for one of the 90 patients with neither C. difficile infection nor colonization
dOther reasons include bladder/kidney/urinary tract infection, closed fracture, urosepsis, cholecystitis, chronic stasis dermatitis, perinephric infection, diverticulitis,
abdominal pain, abdominal hernia, ureteral stone, gangrene, and hip pain
eOther antimicrobial agents include oral vancomycin, clindamycin, daptomycin, gentamicin, Tigecycline, antivirals, and antifungals
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difficile culture result (two of the four CDI cases did
not have C. difficile detected by toxigenic culture but
rather with an enzyme immunoassay). All patients
with a positive C. difficile culture result had a single
isolate recovered and characterized. Two of the four
asymptomatic carriers were colonized with a toxigenic
strain. C. difficile was also detected by WMGS se-
quencing in two of the four asymptomatically colo-
nized patients as well as in two CDI patients with a
positive C. difficile culture result. No other patients
had C. difficile detected by culture or sequencing.
Intestinal microbiota dynamics in patients with C. difficile
colonization or infection
Figure 1 shows variations in the relative abundance of
microbial taxa, overall microbial diversity, as well as bac-
terial and human DNA proportions in relation to hos-
pital exposures and length of stay for patients who
became colonized (Fig. 1a–d) or infected (Fig. 1e–h)
with C. difficile. The human DNA content and the com-
position and diversity of the intestinal microbiota were
highly variable during patient hospitalization. In con-
trast, the proportion of bacterial DNA (measured after
the exclusion of human DNA) was more stable.
We specifically looked at the relative abundance of po-
tentially protective bacterial taxa, including Clostridiales
Family XI Incertae Sedis, Clostridium, and Eubacterium. A
few days prior to or at the time of C. difficile colonization,
three out of four asymptomatic patients exhibited high
relative abundance of these taxa in their intestinal micro-
biota: the relative abundance of Eubacterium was 24.3 % in
patient 30 on the day C. difficile colonization was detected,
the relative abundance of Anaerococcus (a Clostridiales
Family XI Incertae Sedis member) was 31.3 % in patient 87
on the day C. difficile colonization was detected, and the
relative abundance of Clostridium spp. other than C. diffi-
cile (mainly Clostridium bolteae) was 22.2 % in patient 99
4 days prior to C. difficile colonization. We also observed
transient increases in the relative abundance of Clostrid-
ium spp. other than C. difficile (31.0 % [mainly C. bolteae
and Clostridium hathewayi] 13 days prior to CDI diagno-
sis, patient 55) or Clostridiales Family XI Incertae Sedis
(17.4 % 37 days prior to CDI diagnosis, patient 98; data not
shown) in two of the four patients who developed CDI.
However, these increases occurred several days prior to
CDI onset and the corresponding bacterial taxa had a rela-
tive abundance of less than 5 % upon CDI diagnosis. In the
fecal samples (n = 196) from the 90 patients who were nei-
ther colonized nor infected with C. difficile, the median
abundance (range) of Clostridiales Family XI Incertae
Sedis, Clostridium, and Eubacterium was 3.1 (0.0–62.3 %),
0.4 (0.0–67.6 %), and 0.2 % (0.0–37.0 %), respectively.
We observed transient but large increases of Micro-
virus (reaching a relative abundance of ≥50 % in patients
30, 98, and 99), Candida (reaching a relative abundance
of >30 % in patients 98 and 99), and Leuconostoc (reach-
ing a relative abundance of >15 % in patients 98 and 99).
In patients 98 and 99, the increase in the relative abun-
dance of Microvirus was concomitant with an increase
of human read proportions and a decrease of microbial
diversity. In patient 98, striking blooms of Enterococcus
occurred on days 16 (98.0 %), 31 (60.8 %), and 47–62
(64.8–97.5 %) after admission and appeared to follow
the administration of intravenous vancomycin. In the
fecal samples (n = 196) from the 90 patients who were
neither colonized nor infected with C. difficile, the
Table 2 Detection of C. difficile and its toxins in four asymptomatically colonized and four CDI patients
Patient ID Sample type Toxigenic culturea Enzyme
immunoassayc
WMGS sequencing
Culture Toxinb No. of reads Relative abundance
of C. difficile (%)
Asymptomatically colonized
30 Rectal swab Positive Negative ND 8,487,324 0.000
63 Rectal swab Positive Positive ND 10,366,360 0.000
87 Rectal swab Positive Negative ND 4,489,956 0.363
99 Stool Positive Positive ND 14,952,432 0.064
CDI
35 Stoold Negative ND Positive 5,926,081 0.000
36 Stoold Positive Positive ND 7,068,998 0.017
55 Stool Positive Positive Positive 9,950,687 0.003
98 Stool Negative ND Positive 4,337,018 0.000
WMGS whole-metagenome shotgun, ND not done
aPerformed by Dale N. Gerding’s laboratory
bDetected by restriction endonuclease analysis or cytotoxicity assay
cPerformed on a stool sample at the Jewish General Hospital
dA rectal swab was used for WMGS sequencing
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median abundance (range) of Microvirus, Candida,
Leuconostoc, and Enterococcus was 0.0 (0.0–95.6 %), 0.0
(0.0–3.5 %), 0.0 (0.0–51.0 %), and 0.1 % (0.0–91.7 %),
respectively.
Medication use and intestinal microbiota diversity and
composition
We examined the effect of antibiotics as well as other
medications on the diversity and composition of the gut
microbiota. To avoid confounding the results, we ex-
cluded patients who were colonized or infected with C.
difficile (n = 8) from these analyses; therefore, the Clos-
tridium genera does not include C. difficile. Utilization
of fluoroquinolone was moderately correlated with the
use of metronidazole (ρ = 0.45), as were use of penicillin
with use of gentamicin (ρ = 0.57), and use of opioids
with use of laxatives (ρ = 0.41).
Among patients who were neither infected nor colo-
nized with C. difficile, we obtained a mean Shannon di-
versity index of 2.0 (standard deviation 0.6). Exposure to
fluoroquinolones and intravenous vancomycin was associ-
ated with a significant decrease in intestinal microbiota
diversity, while use of opioids was associated with an in-
crease in diversity (Table 3).
A large number of microbial taxa were affected by
common hospital exposures; out of a total of 125 genera
and 59 families identified in at least 5 % of the patients,
88 genera (70.4 %) and 42 families (71.2 %) were associ-
ated with a statistically significant increase or decrease
in relative abundance in univariable analyses (Additional
file 1: Table S1 and Additional file 2: Table S2). With the
exception of non-steroidal anti-inflammatory drugs
(NSAIDs) and opioids, most medications tended to
decrease, rather than increase, the relative abundance of
affected microbial taxa. Carbapenems (33 genera and 13
families) and intravenous vancomycin (34 genera and 15
families) influenced the largest number of microbial taxa.
In multivariable analyses, we specifically looked at the
impact of medications on the relative abundance of mi-
crobial taxa that are thought to be protective against
CDI (Clostridiales Family XI Incertae Sedis, Clostridium,
and Eubacterium) as well as opportunistic microorgan-
isms that can overgrow as a result of antimicrobial use
(Enterococcus and Candida) (Table 4). Use of laxatives
A)
E) F) G) H)
C) D)B)
Fig. 1 Intestinal microbiota dynamics in patients with C. difficile colonization or infection. The figure shows changes in intestinal microbiota
composition (area charts or bar charts for patients with a single measurement), Shannon diversity (dash-dotted line), bacterial DNA content (dotted line),
and human DNA content (solid line) during hospitalization for patients who developed C. difficile colonization (a–d) or infection (e–h). Only those
microbial taxa with a relative abundance of ≥10 % in at least one sample are depicted. The y-axis on the left shows the relative abundance of
microbial taxa or human DNA proportions, while the y-axis on the right shows the Shannon diversity index or bacterial DNA content
(expressed as number of 16S rRNA genes per Mb). The x-axis shows the number of days after hospital admission (day 0). The figures only
display information for the period from hospital admission until the last stool collection. The bars underneath the graphs indicate hospital
exposures: Azithro azithromycin, Ceph cephalosporin, Chemo chemotherapeutic agent, Metro metronidazole, NSAID nonsteroidal anti-inflammatory
drug, Penicillin combination penicillin with β-lactamase inhibitor, PPI proton pump inhibitor, Steroid, glucocorticoid, Vanco IV intravenous vancomycin,
Vanco PO oral vancomycin. The day on which a patient had a positive C. difficile culture (Culture+), the presence of C. difficile infection symptoms, but a
negative C. difficile enzyme immunoassay (CDI symptoms) or a diagnosis of C. difficile infection (CDI diagnosis) is also indicated
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was associated with significant reductions in the relative
abundance of Clostridium and Eubacterium. Adminis-
tration of cephalosporins, fluoroquinolones, or penicillin
with β-lactamase inhibitor was associated with signifi-
cant reductions in the frequency of Clostridiales Family
XI Incertae Sedis. Exposure to fluoroquinolones signifi-
cantly increased the relative abundance of Enterococcus,
while intravenous vancomycin was of borderline signifi-
cance. None of the medications were associated with sig-
nificant variations in the relative abundance of Candida
in multivariable analyses.
Discussion
We previously demonstrated that a reduction in Clostri-
diales Family XI Incertae Sedis is significantly and inde-
pendently associated with the risk of CDI in a distinct
patient population [13]. Certain species within the Eubac-
terium and Clostridium genera, notably C. scindens, have
the ability to convert primary bile acids into secondary bile
acids [16] and have been shown to strongly inhibit C. diffi-
cile in the intestinal microbiota of antibiotic-treated mice
and humans [14]. In this study, asymptomatically colo-
nized patients, but not CDI cases, exhibited elevated
Table 3 Associations between medication use and intestinal microbiota diversity




Estimateb Standard error P valuec
Antibiotics
Cephalosporins 57 81 −0.06 0.07 0.3764
Fluoroquinolones 8 15 −0.20 0.10 0.0367
Penicillin with β-lactamase inhibitors 7 12 −0.17 0.19 0.3805
Carbapenems 5 11 −0.30 0.26 0.2417
Intravenous vancomycin 6 12 −0.41 0.15 0.0080
Other medications
Glucocorticoids 7 13 −0.02 0.17 0.8977
Laxatives 13 24 −0.05 0.09 0.5976
Non-steroidal anti-inflammatory drugs 30 57 0.08 0.08 0.3264
Opioids 23 38 0.13 0.06 0.0202
Proton pump inhibitors 21 54 −0.11 0.10 0.2738
Among patients who were neither colonized nor infected with C. difficile
aReceived within 3 days prior to stool collection
bA positive value indicates that intestinal microbiota diversity was higher among patients exposed to the medication, while a negative value indicates that
intestinal microbiota diversity was lower
cP values were determined by using the GEE-derived robust z scores
Table 4 Multivariable analysis of medications associated with selected microbial taxa
Taxa (outcome) Medicationa Estimateb Standard error P valuec
Clostridium Glucocorticoids 3.72 1.65 0.0239
Laxatives −2.46 0.99 0.0126
Non-steroidal anti-inflammatory drugs −2.11 0.90 0.0197
Eubacterium Fluoroquinolones −0.99 0.44 0.0237
Laxatives −1.21 0.48 0.0115
Clostridiales Family XI Incertae Sedis Cephalosporins −5.78 2.08 0.0055
Fluoroquinolones −5.95 2.21 0.0071
Non-steroidal anti-inflammatory drugs 3.76 1.99 0.0580
Penicillin with β-lactamase inhibitors −5.70 2.54 0.0248
Enterococcus Fluoroquinolones 215.43 102.34 0.0353
Intravenous vancomycin 181.32 95.02 0.0564
Among patients who were neither colonized nor infected with C. difficile. All of the multivariable models were adjusted for age, sex, and duration
of hospitalization
aReceived within 3 days prior to stool collection
bA positive value indicates that the relative abundance of the corresponding taxa was higher among patients exposed to the medication, while a negative value
indicates that the relative abundance was lower
cP values were determined by using the GEE-derived robust z scores
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relative abundance of Clostridiales Family XI Incertae
Sedis, Clostridium, or Eubacterium in their gut shortly
prior to or when C. difficile colonization was detected.
These observations are in agreement with our initial hy-
pothesis and suggest that co-colonization with any of
these potentially protective bacterial taxa might prevent C.
difficile overgrowth in colonized subjects or the transition
from asymptomatic colonization to a full-blown infection.
Previous studies have shown that in the absence of
gross perturbation, the intestinal microbiota of healthy
subjects is relatively stable over time [21, 22]. In con-
trast, we observed dramatic shifts in the composition
and diversity of the intestinal microbiota in patients who
developed C. difficile colonization or infection, as well as
in other hospitalized patients (data not shown). These
observations suggest that single measurements of the in-
testinal microbiota may be problematic when studying
hospitalized patients, in particular, as their microbiota
composition is strongly influenced by their illness and
medical interventions. This offers one explanation why
some studies examining the role of the intestinal micro-
biota on health outcomes may yield conflicting results.
In a previous study, we showed that fecal excretion of
human DNA was significantly increased in patients with
CDI or having other gastrointestinal problems and ap-
peared to be an outcome of intestinal inflammation [23].
In this study, the proportion of human DNA was highly
variable over time but was observed to be higher prior
to CDI development in two of the four cases. In some of
our patients, increases in the proportion of human DNA
were concomitant with a reduction of microbial diversity
and increases in the relative abundance of Microvirus.
Microviruses are single-stranded DNA bacteriophages
that infect enterobacteria and are commonly found in
human gut samples [24]. High levels of human DNA ex-
cretion have been associated with a reduction of intes-
tinal microbiota diversity [23].
One of the patients who developed CDI (patient 98)
exhibited striking blooms of Enterococcus (with frequen-
cies reaching 98 %) on multiple occasions during his
hospitalization. These blooms appeared to follow the
administration of intravenous vancomycin and may
represent an overgrowth of vancomycin-resistant Entero-
coccus (VRE). Studies have shown that the use of intra-
venous vancomycin is significantly associated with VRE
colonization or infection [25]. Although we do not know
whether this patient actually carried VRE or developed
sepsis, Ubeda et al. have previously shown that intestinal
domination by VRE typically precedes bloodstream in-
fection in hospitalized patients [26]. In the cohort of pa-
tients who were neither colonized nor infected with C.
difficile, we confirm that the use of intravenous vanco-
mycin is associated with increases in the relative abun-
dance of Enterococcus.
Receipt of opioids was associated with significant in-
creases in microbial diversity. This medication typically
delays gastrointestinal transit time and may facilitate mi-
crobial growth in the colon, thereby increasing diversity.
Significant reductions in intestinal microbiota diversity
were only associated with the use of fluoroquinolones
and intravenous vancomycin. Surprisingly, exposure to
other antibiotics and PPIs did not reduce overall micro-
biota diversity in our cohort but did influence the rela-
tive abundance of numerous microbial taxa. The
association between PPIs and CDI development is still a
controversial issue [27]. The notion of reduced micro-
biota diversity may suggest that the number and relative
abundance of microbial taxa are both declining. How-
ever, our study suggests that microbiota dynamics are
much more complex; many taxa are being depleted
while others are blooming. Therefore, measurement of
the overall diversity is masking important distortions in
the composition of the microbial community.
In multivariable analyses, we showed that the use of
laxatives is associated with significant reductions in the
relative abundance of Clostridium and Eubacterium; cer-
tain species among these genera may confer protection
against CDI via the production of secondary bile acids.
However, in a post hoc analysis, the Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway corresponding
to secondary bile acid biosynthesis (ko00121) was not
detected in any our metagenomic samples. Laxatives ac-
celerate gastrointestinal transit time and may have detri-
mental effects on the intestinal microbiota. van der
Wulp et al. previously showed that treatment with poly-
ethylene glycol (an osmotic laxative) changes the com-
position of the intestinal microbiota and decreases the
production of secondary bile acids in rats [28]. We also
demonstrated that the use of cephalosporins, fluoroqui-
nolones, and penicillin with β-lactamase inhibitors is sig-
nificantly and independently associated with reductions
in the relative abundance of Clostridiales Family XI
Incertae Sedis representatives. Since cephalosporin and
fluoroquinolone exposure, as well as depletions of Clos-
tridiales Family XI Incertae Sedis, have been associated
with CDI risk [13], this provides a potential explanation
for why these antibiotics increase the susceptibility to
CDI in hospitalized patients.
We observed discrepancies in the detection of C. diffi-
cile or its toxins by culture, WMGS sequencing, and en-
zyme immunoassay. In two of the four asymptomatically
colonized patients, C. difficile was detected by culture
but not by WMGS sequencing. In two of the four CDI
cases, C. difficile could not be detected, either by culture
or sequencing (their CDI diagnosis was based on a posi-
tive enzyme immunoassay performed at the hospital).
This may be due to a low organism load, the lack of bio-
mass collected with the rectal swabs, or insufficient
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sequencing depth. One patient (patient 98) received
vancomycin and metronidazole treatment for presump-
tive CDI prior to the actual diagnosis by enzyme im-
munoassay, which may have reduced the quantity of C.
difficile organisms available for detection.
The number of patients who developed C. difficile
colonization or infection was limited in our study; there-
fore, we could not perform statistical analyses to assess
the role of hospital exposures and microbial taxa for pa-
tients with these outcomes. In all of the four patients
who developed asymptomatic colonization, C. difficile
was detected by culture in the last stool collected prior
to patient discharge. Therefore, we could not determine
whether C. difficile colonization was transient (present
in only one occasion) or not in these patients. In the full
cohort, insufficient numbers of patients exposed to cer-
tain medications (e.g., metronidazole and cotrimoxazole)
or colonized by specific microbial taxa (e.g., Aerococcus
and Microbacteriaceae) precluded statistical analyses.
Diet and other factors such as underlying disease state
can affect the intestinal microbiota and could still con-
found the associations identified in our study.
Conclusions
The integrity of the intestinal microbiota is intricately
related to the health of the host. In this study, we show
that the diversity and composition of the intestinal
microbiota in hospitalized patients is highly dynamic.
Use of antibiotics, as well as other non-antimicrobial
medications, particularly laxatives, has a profound and
rapid effect on the structure of the intestinal microbiota
and significantly decreased the relative abundance of key
bacterial taxa that may be involved in CDI protection.
Our results also support the hypothesis that co-
colonization with key bacterial taxa such as Clostridiales
Family XI Incertae Sedis, Clostridium, or Eubacterium
may prevent C. difficile overgrowth or the transition
from asymptomatic C. difficile colonization to CDI. A
better understanding of CDI pathogenesis, including the
medical exposures that undermine the effectiveness of
colonization resistance and the specific microbiota alter-
ations that allow C. difficile to infect the gut, will con-
tribute to our ability to develop novel clinical strategies
to prevent or treat this life-threatening infection.
Methods
Patient recruitment and follow-up
Research subjects were recruited as part of a prospective
cohort study conducted at the Jewish General Hospital
(JGH) in Montréal between October 2009 and April
2011. Patients ≥60 years of age, who were expected to
stay more than 2 days in the hospital at the time of study
enrolment, and who had received antimicrobials in the
previous 48 h or were expected to receive some in the
next 24 h were eligible to participate in the study. Pa-
tients admitted to the hospital for CDI were excluded.
Subjects were enrolled in the study within 5 days after
admission to selected medical wards or surgical units.
Patients were followed for 60 days after study enrolment
or 30 days after hospital discharge (whichever came first)
to ascertain the development of CDI. CDI cases were
followed for 60 days after successfully completing CDI
treatment to monitor the development of recurrent CDI.
Ethics, consent, and permissions
All study participants provided informed written con-
sent. The Research Ethics Boards of the JGH (08-118A)
and the McGill University Health Centre (11-205 GEN)
approved the research protocol.
Sample and epidemiologic data collection
Fecal specimens were obtained from each patient at
study enrollment, every 3 days during hospitalization, at
the onset of diarrhea (if applicable), and at discharge.
The samples were collected as bulk stool or with the use
of a rectal swab if the patient was not producing stool.
Rectal swabs are a convenient means of sampling the
human gut and give highly reproducible microbiota pro-
files that can closely resemble that of fecal samples [29].
Epidemiologic information was extracted from the pa-
tients’ medical charts and included patient demographics,
previous hospitalizations, reason of admission, disease se-
verity index, dates of admission and discharge, CDI diag-
nosis, and the use of antimicrobials and other medications
during hospitalization (with corresponding start and stop
dates).
Toxigenic C. difficile culture
Toxigenic culture test results were provided as a
courtesy of Dr. Dale N. Gerding (Hines VA Hospital
and Loyola University Chicago Stritch School of
Medicine, IL). Briefly, stool or rectal swab specimens
were streaked onto selective pre-reduced cefoxitin-
cycloserine-fructose agar supplemented with taurocholate
(TCCFA) and incubated anaerobically for 48 h. Presump-
tive identification of C. difficile was based on typical col-
ony morphology. If colony morphologies suggested that a
mixture of C. difficile strains were present, multiple col-
onies were picked and saved individually. All rectal swabs
were also inoculated onto non-selective blood agar to de-
tect the growth of intestinal microbiota and confirm
proper sampling technique, thereby excluding the possi-
bility of false-negative results on the TCCFA. Purified iso-
lates were characterized by restriction endonuclease
analysis (REA) to determine their toxin classification [30].
The Bartels Cytotoxicity Assay (Trinity Biotech) was per-
formed to determine the presence of toxin B in C. difficile
isolates with an undetermined REA group.
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Study definitions
CDI was defined as follows: (i) the presence of symp-
toms (diarrhea, fever, abdominal pain, or ileus) and a
positive C. difficile enzyme immunoassay (ImmunoCard
Toxins A&B, Meridian Bioscience, Inc.) or toxigenic cul-
ture, (ii) an endoscopic diagnosis of pseudomembranes,
or (iii) a pathological/histological diagnosis of CDI. Diar-
rhea was defined as the passage of ≥3 new unformed
stools within 24 h. Recurrent CDI was defined as a CDI
diagnosis that occurs within 60 days after successfully
completing the treatment for the initial episode of CDI.
Asymptomatic C. difficile colonization was defined as a
positive stool culture for C. difficile and the absence of a
CDI diagnosis during follow-up. Colonization or infec-
tion was considered hospital-acquired if the diagnosis
was made ≥48 h after hospital admission and during the
study follow-up period.
WMGS sequencing and data analysis
Total DNA was extracted from rectal swabs with use
of the DNA IQ System (Promega) and from bulk
stool aliquots with the use of the QIAamp DNA Stool
Mini Kit (Qiagen). Multiplexed DNA libraries were
prepared according to a previously described protocol
that allows the generation of libraries from low
amounts of input DNA [31]. WMGS sequencing was
performed with 150-nucleotide read lengths on the
Illumina HiSeq 2000 and 2500 platforms at the
McGill University and Génome Québec Innovation
Centre. Up to 14 samples were multiplexed in each se-
quencing lane. Reads derived from the human genome
were identified and removed with BMTagger [32]. Add-
itional quality filtering steps included the trimming of se-
quencing adapters and low-quality bases from the 3′ end
of reads as well as the removal of short (<60 bases) and
duplicate reads [33, 34]. We retrieved all reads containing
the V1–V3 reverse primer sequence (which targets a seg-
ment of the 16S rRNA gene) [35] and their 3′ sequences
in order to obtain 55-mers originating with the primer se-
quence. The frequency of 16S rRNA genes (55-mers) per
Mb of sequence data was used as a measure of bacterial
DNA content in each sample. High-quality reads were also
analyzed by MetaPhlAn2 [36] in order to determine the
family, genus, and species level relative abundances. Diver-
sity was calculated at the genus level with the Shannon
index. HUMAnN version 0.99 [37] was used in conjunc-
tion with RAPSearch2 [38] and the KEGG database [39]
to evaluate the presence of the pathway for secondary bile
acid biosynthesis (ko00121) in each metagenomic sample.
Statistical analyses
We provide a descriptive analysis of microbiota com-
position for patients who were either colonized or in-
fected by C. difficile; we specifically examined changes
in the relative abundance of potential CDI-protecting mi-
croorganisms (i.e., Clostridiales Family XI Incertae Sedis,
Clostridium, and Eubacterium). In order to assess the rela-
tionship between hospital exposures (e.g., antibiotics and
other medications) and either overall microbiota diversity
or relative abundance of microbiota members, we used
generalized estimating equation (GEE) analyses with a
Gaussian link. GEE takes into account the multiple sam-
ples per subject and the likelihood that the microbiota
profiles are correlated over time within patients. Microbial
diversity and relative abundances were modeled using a
log transformation. In these analyses, we excluded patients
who were colonized or infected with C. difficile and con-
sidered only those microbial taxa and medications that
were present in or administered to at least 5 % of the
patients (i.e., cephalosporins, fluoroquinolones, penicillin
with β-lactamase inhibitors, carbapenems, intravenous
vancomycin, glucocorticoids, laxatives, NSAIDs, opioids,
and PPIs). Use of medication was treated as a binary
variable with “1” indicating exposure within 1 to 3 days
prior to stool collection and “0” indicating otherwise. We
included exposure to intravenous vancomycin in our
analyses, as evidence suggests that substantial amounts
of the drug can be excreted in the bowel and may
therefore affect the intestinal microbiota [40]. Multivar-
iable analyses were used in order to take into account
the correlation in the use of certain medications. In
addition to the medications mentioned above, all multi-
variable models included adjustment for age, sex, and
duration of hospitalization. Final multivariable models
retained significant exposure variables at a p value of
<0.05. A positive estimate value indicates that the cor-
responding exposure is associated with an increase in
either overall microbiota diversity or relative abundance
of the given microbial taxa. All statistical analyses were
performed in R [41]; GEE was performed using the gee-
pack package. P values were determined by using the
GEE-derived robust z scores.
Availability of supporting data
The sequence data supporting the results of this article
are available in the National Center for Biotechnology




Additional file 1: Table S1. Significant associations between
medication use and intestinal microbiota genera (univariable analysis).
(XLSX 433 KB)
Additional file 2: Table S2. Significant associations between
medication use and intestinal microbiota families (univariable analysis).
(XLSX 385 KB)
Vincent et al. Microbiome  (2016) 4:12 Page 9 of 11
Abbreviations
CDI: Clostridium difficile infection; PPI: proton pump inhibitors;
WMGS: whole metagenome shotgun; TCCFA: cefoxitin-cycloserine-fructose
agar supplemented with taurocholate; REA: restriction endonuclease analysis;
GEE: generalized estimating equations; rRNA: ribosomal RNA;
VRE: vancomycin-resistant Enterococcus; JGH: Jewish General Hospital;
NSAID: non-steroidal anti-inflammatory drug.
Competing interests
MAM has been an employee of bioMerieux since October 2012. The other
authors declare that they have no competing interests.
Authors’ contributions
CV prepared the sequencing libraries, performed the bioinformatic analyses,
participated in data analysis and interpretation, and drafted the manuscript.
MAM provided patient epidemiologic information and clinical samples and
participated in data analysis and interpretation. TJE performed the statistical
analyses. SM assisted with bioinformatic analyses. KD participated in data
analysis and interpretation. ARM conceived and designed the study,
participated in data analysis and interpretation, and helped to draft the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank Dr. Dale N. Gerding for the toxigenic C.
difficile culture, REA typing, and cytotoxicity assays done as part of a parallel
study on the same patient cohort. They also thank the clinical research staff
at the JGH, Jennifer Eastmond, Romina Gheorghe, and Sophie Florencio, for
their valuable help with the collection of clinical samples and the chart
reviews. This work was supported by a Pfizer ASPIRE Award in Antibacterial
Research [WS1954106 to A.R.M.], a Studentship from the Research Institute of
the McGill University Health Centre [C.V.], as well as a Frederick Banting and
Charles Best Canada Graduate Scholarship (Doctoral Award) from the
Canadian Institutes of Health Research [GSD-113375 to C.V.]. The funding
bodies had no role in the study design, in the collection, analysis, and
interpretation of data, in the writing of the manuscript, and in the decision
to submit the manuscript for publication.
Author details
1Department of Microbiology and Immunology, McGill University, Montréal,
Québec, Canada. 2Génome Québec Innovation Centre, McGill University,
Montréal, Québec, Canada. 3Jewish General Hospital, Montréal, Québec,
Canada. 4Devil’s Staircase Consulting, North Vancouver, British Columbia,
Canada. 5New York Genome Center, New York, NY, USA. 6Department of
Human Genetics, McGill University, Montréal, Québec, Canada. 7School of
Population and Public Health, University of British Columbia, Vancouver,
British Columbia, Canada.
Received: 4 September 2015 Accepted: 14 February 2016
References
1. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al.
Burden of Clostridium difficile infection in the United States. N Engl J Med.
2015;372(9):825–34. doi:10.1056/NEJMoa1408913.
2. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR,
Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of
Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–98.
doi:10.1038/ajg.2013.4. quiz 99.
3. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated
disease in North America and Europe. Clin Microbiol Infect. 2006;12 Suppl 6:
2–18. doi:10.1111/j.1469-0691.2006.01580.x.
4. Kelly CP, LaMont JT. Clostridium difficile—more difficult than ever. N Engl J
Med. 2008;359(18):1932–40. doi:10.1056/NEJMra0707500.
5. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk
factors and management. Nat Rev Gastroenterol Hepatol. 2011;8(1):17–
26. doi:10.1038/nrgastro.2010.190.
6. Owens Jr RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-
associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;
46 Suppl 1:S19–31. doi:10.1086/521859.
7. Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al.
Emergence of fluoroquinolones as the predominant risk factor for
Clostridium difficile-associated diarrhea: a cohort study during an epidemic
in Quebec. Clin Infect Dis. 2005;41(9):1254–60. doi:10.1086/496986.
8. Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R, Kalaitzakis E, Sigurdardottir
O, Bjornsson ES. Risk factors for Clostridium difficile toxin-positive diarrhea: a
population-based prospective case-control study. Eur J Clin Microbiol Infect
Dis. 2012;31(10):2601–10. doi:10.1007/s10096-012-1603-0.
9. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ.
Asymptomatic carriers are a potential source for transmission of epidemic
and nonepidemic Clostridium difficile strains among long-term care facility
residents. Clin Infect Dis. 2007;45(8):992–8. doi:10.1086/521854.
10. Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O’Connor L, et al.
Diverse sources of C. difficile infection identified on whole-genome
sequencing. N Engl J Med. 2013;369(13):1195–205. doi:10.1056/
NEJMoa1216064.
11. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary
symptomless colonisation by Clostridium difficile and decreased risk of
subsequent diarrhoea. Lancet. 1998;351(9103):633–6. doi:10.1016/S0140-
6736(97)08062-8.
12. Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E.
Colonization with toxinogenic C. difficile upon hospital admission, and risk
of infection: a systematic review and meta-analysis. Am J Gastroenterol.
2015;110(3):381–90. doi:10.1038/ajg.2015.22. quiz 91.
13. Vincent C, Stephens DA, Loo VG, Edens TJ, Behr MA, Dewar K, et al.
Reductions in intestinal Clostridiales precede the development of
nosocomial Clostridium difficile infection. Microbiome. 2013;1(18):1–11.
14. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, et al. Precision
microbiome reconstitution restores bile acid mediated resistance to
Clostridium difficile. Nature. 2015;517(7533):205–8. doi:10.1038/nature13828.
15. Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, et al.
Administration of spores of nontoxigenic Clostridium difficile strain M3 for
prevention of recurrent C difficile infection: a randomized clinical trial. JAMA.
2015;313(17):1719–27. doi:10.1001/jama.2015.3725.
16. Guérard P. Metabolism of cholesterol and bile acids by the gut microbiota.
Pathogens. 2014;3:14–24.
17. Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton
pump inhibitor reduces microbial diversity: implications for Clostridium difficile
susceptibility. Microbiome. 2014;2:42. doi:10.1186/2049-2618-2-42.
18. Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, et
al. Effect of antibiotic therapy on the density of vancomycin-resistant
enterococci in the stool of colonized patients. N Engl J Med. 2000;343(26):
1925–32. doi:10.1056/NEJM200012283432604.
19. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the
ecological balance of human microflora. Lancet Infect Dis. 2001;1(2):101–14.
doi:10.1016/S1473-3099(01)00066-4.
20. Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC,
et al. Proton pump inhibitors alter specific taxa in the human
gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015.
doi:10.1053/j.gastro.2015.06.043.
21. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman
AL, et al. The long-term stability of the human gut microbiota. Science.
2013;341(6141):1237439. doi:10.1126/science.1237439.
22. Jalanka-Tuovinen J, Salonen A, Nikkila J, Immonen O, Kekkonen R, Lahti L, et
al. Intestinal microbiota in healthy adults: temporal analysis reveals
individual and common core and relation to intestinal symptoms. PLoS
One. 2011;6(7):e23035. doi:10.1371/journal.pone.0023035.
23. Vincent C, Mehrotra S, Loo VG, Dewar K, Manges AR. Excretion of host DNA
in feces is associated with risk of Clostridium difficile infection. J Immunol
Res. 2015;2015:246203. doi:10.1155/2015/246203.
24. Fane BA, Brentlinger KL, Burch AD, Chen M, Hafenstein S, Moore E, et al. The
Microviridae. The Bacteriophages. 2nd ed. Oxford: Oxford University Press; 2011.
25. Gerding DN. Is there a relationship between vancomycin-resistant
enterococcal infection and Clostridium difficile infection? Clin Infect Dis.
1997;25 Suppl 2:S206–10.
26. Ubeda C, Taur Y, Jenq RR, Equinda MJ, Son T, Samstein M, et al.
Vancomycin-resistant Enterococcus domination of intestinal microbiota is
enabled by antibiotic treatment in mice and precedes bloodstream invasion
in humans. J Clin Invest. 2010;120(12):4332–41. doi:10.1172/JCI43918.
27. Canadian Agency for Drugs and Technologies in Health. Proton pump
inhibitors and C. difficile: a review of the clinical evidence. 2014. https://
www.cadth.ca/sites/default/files/pdf/htis/dec-2014/
RC0582%20PPIs%20and%20C%20Difficile%20Final.pdf.
Vincent et al. Microbiome  (2016) 4:12 Page 10 of 11
28. van der Wulp MY, Derrien M, Stellaard F, Wolters H, Kleerebezem M,
Dekker J, et al. Laxative treatment with polyethylene glycol decreases
microbial primary bile salt dehydroxylation and lipid metabolism in the
intestine of rats. Am J Physiol Gastrointest Liver Physiol. 2013;305(7):
G474–82. doi:10.1152/ajpgi.00375.2012.
29. Budding AE, Grasman ME, Eck A, Bogaards JA, Vandenbroucke-Grauls CM,
van Bodegraven AA, et al. Rectal swabs for analysis of the intestinal
microbiota. PLoS One. 2014;9(7):e101344. doi:10.1371/journal.pone.0101344.
30. Clabots CR, Johnson S, Bettin KM, Mathie PA, Mulligan ME, Schaberg DR, et
al. Development of a rapid and efficient restriction endonuclease analysis
typing system for Clostridium difficile and correlation with other typing
systems. J Clin Microbiol. 1993;31(7):1870–5.
31. Meyer M, Kircher M. Illumina sequencing library preparation for highly
multiplexed target capture and sequencing. Cold Spring Harb Protoc. 2010;
2010(6):pdb prot5448. doi:10.1101/pdb.prot5448.
32. BMTagger. ftp://ftp.ncbi.nlm.nih.gov/pub/agarwala/bmtagger/.
33. Niu B, Fu L, Sun S, Li W. Artificial and natural duplicates in
pyrosequencing reads of metagenomic data. BMC Bioinformatics. 2010;
11:187. doi:10.1186/1471-2105-11-187.
34. Martin M. Cutadapt removes adapter sequences from high-throughput
sequencing reads. EMBnet J. 2011;17(1):10–2.
35. Jumpstart Consortium Human Microbiome Project Data Generation
Working Group. 16S 454 sequencing protocol. 2010. http://hmpdacc.org/
doc/16S_Sequencing_SOP_4.2.2.pdf.
36. Truong DT, Franzosa EA, Tickle TL, Scholz M, Weingart G, Pasolli E, et al.
MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nat Methods.
2015;12(10):902–3. doi:10.1038/nmeth.3589.
37. Abubucker S, Segata N, Goll J, Schubert AM, Izard J, Cantarel BL, et al.
Metabolic reconstruction for metagenomic data and its application to
the human microbiome. PLoS Comput Biol. 2012;8(6):e1002358.
doi:10.1371/journal.pcbi.1002358.
38. Zhao Y, Tang H, Ye Y. RAPSearch2: a fast and memory-efficient protein
similarity search tool for next-generation sequencing data. Bioinformatics.
2012;28(1):125–6. doi:10.1093/bioinformatics/btr595.
39. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes.
Nucleic Acids Res. 2000;28(1):27–30.
40. Currie BP, Lemos-Filho L. Evidence for biliary excretion of vancomycin into
stool during intravenous therapy: potential implications for rectal
colonization with vancomycin-resistant enterococci. Antimicrob Agents
Chemother. 2004;48(11):4427–9. doi:10.1128/AAC.48.11.4427-4429.2004.
41. The R project for statistical computing. http://www.r-project.org/.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Vincent et al. Microbiome  (2016) 4:12 Page 11 of 11
